De Felice, D., Alaimo, A., Bressan, D., Genovesi, S., Marmocchi, E., Annesi, N., Beccaceci, G., Dalfovo, D., Cutrupi, F., Medaglia, S., Foletto, V., Lorenzoni, M., Gandolfi, F., Kannan, S., Verma, C. S., Vasciaveo, A., Shen, M. M., Romanel, A., Chiacchiera, F., … Lunardi, A. (2024). Rarγ-Foxa1 signaling promotes luminal identity in prostate progenitors and is disrupted in prostate cancer. EMBO Reports. https://doi.org/10.1038/s44319-024-00335-y

Rathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D., Lakhani, N., Hawley, J. E., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K. D., Emamekhoo, H., Reichert, Z. R., Nguyen, M. H., Wells, A. L., Kandimalla, R., Liu, C., Suryawanshi, S., Han, J., Wu, J., … Armstrong, A. J. (2024). Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2024.09.005

Leuva, H., Zhou, M., Jamaleddine, N., Meseha, M., Faiena, I., Anna Park, Y.-H., McWilliams, G., Luhrs, C., Maxwell, K. N., Von Hoff, D., Bates, S. E., & Fojo, T. (2024). Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent -rate method ideal for real-world analyses. EBioMedicine, 107, 105288. https://doi.org/10.1016/j.ebiom.2024.105288

Carmichael, J., Figueiredo, I., Gurel, B., Beije, N., Yuan, W., Rekowski, J., Seed, G., Carreira, S., Bertan, C., Fenor de la Maza, M. de L. D., Chandran, K., Neeb, A., Welti, J., Gallagher, L., Bogdan, D., Crespo, M., Riisnaes, R., Ferreira, A., Miranda, S., … de Bono, J. (2024). RNASEH2B loss and PARP inhibition in advanced prostate cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci178278

Rayn, K., Deutsch, I., Jeffers, B., Lee, A., Lavrova, E., Gallitto, M., Mayeda, M., Hwang, M., Yu, J., Spina, C., & Koutcher, L. (2024). Multiparametric MRI as a Predictor of PSA Response in Patients Undergoing Stereotactic Body Radiation Therapy for Prostate Cancer. Advances in Radiation Oncology, 9(3), 101408. https://doi.org/10.1016/j.adro.2023.101408

Stein, M. N., Hawley, J., Zibelman, M., Pachynski, R., Dreicer, R., Zarrabi, K. K., Miles, B., Hauke, R. J., Marshall, M. A., Jones, B., Wheeler, V., Sebastian, S., Anderson, K., Vardeu, A., Davis, C., Bendall, J., & Shore, N. (2023). 665 Immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer: A clinical trial in progress. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0665

Hawley, J. E., Obradovic, A. Z., Dallos, M. C., Lim, E. A., Runcie, K., Ager, C. R., McKiernan, J., Anderson, C. B., Decastro, G. J., Weintraub, J., Virk, R., Lowy, I., Hu, J., Chaimowitz, M. G., Guo, X. V., Zhang, Y., Haffner, M. C., Worley, J., Stein, M. N., … Drake, C. G. (2023). Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell, 41(11), 1972-1988.e5. https://doi.org/10.1016/j.ccell.2023.10.006

Baljevic, M., Moreau, P., Tuchman, S., Callander, N., Lentzsch, S., Van Domelen, D., Bentur, O., Monge, J., & Biran, N. (2023). P-232 Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. Clinical Lymphoma Myeloma and Leukemia, 23, S163. https://doi.org/10.1016/s2152-2650(23)01850-5

Madan, R. A., Bilusic, M., Stein, M. N., Donahue, R. N., Arlen, P. M., Karzai, F., Plimack, E., Wong, Y.-N., Geynisman, D. M., Zibelman, M., Mayer, T., Strauss, J., Chen, G., Rauckhorst, M., McMahon, S., Couvillon, A., Steinberg, S., Figg, W. D., Dahut, W. L., … Gulley, J. L. (2023). Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. The Oncologist, 28(7), 642-e561. https://doi.org/10.1093/oncolo/oyad058

Vasciaveo, A., Arriaga, J. M., de Almeida, F. N., Zou, M., Douglass, E. F., Picech, F., Shibata, M., Rodriguez-Calero, A., de Brot, S., Mitrofanova, A., Chua, C. W., Karan, C., Realubit, R., Pampou, S., Kim, J. Y., Afari, S. N., Mukhammadov, T., Zanella, L., Corey, E., … Abate-Shen, C. (2022). OncoLoop: A Network-Based Precision Cancer Medicine Framework. Cancer Discovery, 13(2), 386–409. https://doi.org/10.1158/2159-8290.cd-22-0342

Cholesterol Triggers Nuclear Co-Association of Androgen Receptor, p160 Steroid Coactivators, and p300/CBP-Associated Factor Leading to Androgenic Axis Transactivation in Castration-Resistant Prostate Cancer. (2022). Cellular Physiology and Biochemistry, 56(S4), 1–15. https://doi.org/10.33594/000000592

Hou, J., Goodman, O., Berz, D., Yao, L., & Soni, N. (2022). 733 A phase 2 study of vudalimab (XmAb®20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer. Regular and Young Investigator Award Abstracts, A765–A765. https://doi.org/10.1136/jitc-2022-sitc2022.0733

Stein, M., Goodman, O., Dorff, T., Narayan, V., Avitia, J., McKay, R., Nordquist, L., Rettig, M., Schweizer, M., Thomas, R., Silverman, M., Yao, L., Clynes, R., & Shorr, J. (2022). 668 A phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer. Regular and Young Investigator Award Abstracts, A698–A698. https://doi.org/10.1136/jitc-2022-sitc2022.0668

Kim, M. S., Naidoo, D., Hazra, U., Quiver, M. H., Chen, W. C., Simonti, C. N., Kachambwa, P., Harlemon, M., Agalliu, I., Baichoo, S., Fernandez, P., Hsing, A. W., Jalloh, M., Gueye, S. M., Niang, L., Diop, H., Ndoye, M., Snyper, N. Y., Adusei, B., … Lachance, J. (2022). Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa. Genome Biology, 23(1). https://doi.org/10.1186/s13059-022-02766-z

Lim, E., Reeves, J., Gandhi, S., Spigel, D. R., Arrowsmith, E., George, D. J., Karlix, J., Pouliot, G., Hattersley, M., Gangl, E., James, G., Thompson, J., Russell, D., Patel, B., Kumar, R., & Falchook, G. S. (2022). 1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology, 33, S1182–S1183. https://doi.org/10.1016/j.annonc.2022.07.1882

Stein, M. N., Fong, L., Tutrone, R., Mega, A., Lam, E. T., Parsi, M., Vangala, S., Gutierrez, A. A., & Haas, N. B. (2022). ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. The Oncologist, 27(6), 453–461. https://doi.org/10.1093/oncolo/oyac048

Cambuli, F., Foletto, V., Alaimo, A., De Felice, D., Gandolfi, F., Palumbieri, M. D., Zaffagni, M., Genovesi, S., Lorenzoni, M., Celotti, M., Bertossio, E., Mazzero, G., Bertossi, A., Bisio, A., Berardinelli, F., Antoccia, A., Gaspari, M., Barbareschi, M., Fiorentino, M., … Lunardi, A. (2022). Intra‐epithelial non‐canonical Activin A signaling safeguards prostate progenitor quiescence. EMBO Reports, 23(5). Portico. https://doi.org/10.15252/embr.202154049

Abate-Shen, C., & Nunes de Almeida, F. (2022). Establishment of the LNCaP Cell Line – The Dawn of an Era for Prostate Cancer Research. Cancer Research, 82(9), 1689–1691. https://doi.org/10.1158/0008-5472.can-22-1065